Denali Therapeutics Inc Share Price Today: Live Updates & Key Insights
Denali Therapeutics Inc share price today is $23.37, up -1.32%. The stock opened at $23.64 against the previous close of $23.42, with an intraday high of $23.64 and low of $22.64.
Denali Therapeutics Inc Share Price Chart
Denali Therapeutics Inc
Denali Therapeutics Inc Share Price Performance
Denali Therapeutics Inc Institutional Holdings
Denali Therapeutics Inc Market Status
Denali Therapeutics Inc Fundamentals
Market Cap 3716.98 M
PB Ratio 4.0513
PE Ratio 0.0
Enterprise Value 2798.75 M
Total Assets 1144.85 M
Volume 1162875
Denali Therapeutics Inc Company Financials
About Denali Therapeutics Inc & investment objective
Company Information Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Organisation Biotechnology
Employees 507
Industry Biotechnology
CEO Dr. Ryan J. Watts Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Denali Therapeutics Inc FAQs
What is the share price of Denali Therapeutics Inc today?
The current share price of Denali Therapeutics Inc is $23.37.
Can I buy Denali Therapeutics Inc shares in India?
Yes, Indian investors can buy Denali Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.
How to buy Denali Therapeutics Inc shares in India?
You can easily invest in Denali Therapeutics Inc shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Denali Therapeutics Inc shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Denali Therapeutics Inc.
Can I buy fractional shares of Denali Therapeutics Inc?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Denali Therapeutics Inc?
Denali Therapeutics Inc has a market cap of $3716.98 M.
In which sector does Denali Therapeutics Inc belong?
Denali Therapeutics Inc operates in the Biotechnology sector.
What documents are required to invest in Denali Therapeutics Inc stocks?
To invest, you typically need:
What is the PE and PB ratio of Denali Therapeutics Inc?
The PE ratio of Denali Therapeutics Inc is N/A and the PB ratio is 4.05.